Citius Oncology (CTOR) Gross Profit (2025 - 2026)

Citius Oncology (CTOR) posted quarterly Gross Profit of $1.3 million for Q1 2026, down 57.58% quarter-over-quarter from $3.2 million in Q4 2025.

Citius Oncology (CTOR) Gross Profit (2025 - 2026) Analysis & Trends

Citius Oncology (CTOR) has reported Gross Profit for 2 consecutive years, with $1.3 million the latest figure, recorded in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	44.07 Bn	43.10 Bn	-
2	Teva Pharmaceutical Industries	43.41 Bn	39.75 Bn	2.15 Bn
3	Zoetis	31.83 Bn	30.15 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.77 Bn	22.97 Bn	5.10 Bn
5	United Therapeutics	22.27 Bn	19.61 Bn	683.80 Mn
6	Viatris	18.76 Bn	17.87 Bn	1.46 Bn
7	Neurocrine Biosciences	15.65 Bn	15.26 Bn	935.80 Mn
8	Elanco Animal Health	11.93 Bn	11.40 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.16 Bn	10.00 Bn	-
10	Citius Oncology	76.95 Mn	76.95 Mn	1.00 Mn

Download Data